If you have been reading about nuclear receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-06-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
== Signs and symptoms == Early symptoms are malaise and lethargy. After one to three months, patients develop shortness of breath and bone pain. Myalgias may occur because of reduced carnitine production. Other symptoms include skin changes with roughness, easy bruising, and petechiae, gum disease, loosening of teeth, poor wound healing, and emotional changes (which may appear before any physical changes). Dry mouth and dry eyes similar to Sjögren's syndrome may occur. In the late stages, jaundice, generalised edema, oliguria, neuropathy, fever, convulsions, and eventual death are frequently seen. Signs of scurvy also include hypotension, pulmonary hypertension, and an enlarged heart.
=== Tendon-bone interface === In addition to its role in load-bearing joints, cartilage serves a crucial function as a gradient material between softer tissues and bone. Mechanical gradients are crucial for the body's function, and for complex artificial structures including joint implants. Interfaces with mismatched material properties lead to areas of high stress concentration which, over the millions of loading cycles experienced by human joins over a lifetime, would eventually lead to failure. For example, the elastic modulus of human bone is roughly 20 GPa while the softer regions of cartilage can be about 0.5 to 0.9 MPa. When there is a smooth gradient of materials properties, however, stresses are distributed evenly across the interface, which puts less wear on each individual part. The body solves this problem with stiffer, higher modulus layers near bone, with high concentrations of mineral deposits such as hydroxyapatite. Collagen fibers (which provide mechanical stiffness in cartilage) in this region are anchored directly to bones, reducing the possible deformation. Moving closer to soft tissue into the region known as the tidemark, the density of chondrocytes increases and collagen fibers are rearranged to optimize for stress dissipation and low friction. The outermost layer near the articular surface is known as the superficial zone, which primarily serves as a lubrication region.
The formation of bone is called ossification. During the fetal stage of development this occurs by two processes: intramembranous ossification and endochondral ossification. Intramembranous ossification involves the formation of bone from connective tissue whereas endochondral ossification involves the formation of bone from cartilage. Intramembranous ossification mainly occurs during formation of the flat bones of the skull but also the mandible, maxilla, and clavicles; the bone is formed from connective tissue such as mesenchyme tissue rather than from cartilage. The process includes: the development of the ossification center, calcification, trabeculae formation and the development of the periosteum. Endochondral ossification occurs in long bones and most other bones in the body; it involves the development of bone from cartilage. This process includes the development of a cartilage model, its growth and development, development of the primary and secondary ossification centers, and the formation of articular cartilage and the epiphyseal plates. Endochondral ossification begins with points in the cartilage called "primary ossification centers". They mostly appear during fetal development, though a few short bones begin their primary ossification after birth. They are responsible for the formation of the diaphyses of long bones, short bones and certain parts of irregular bones. Secondary ossification occurs after birth and forms the epiphyses of long bones and the extremities of irregular and flat bones.
The advanced heavy-water reactor is one of the few proposed large-scale uses of thorium. The IAEA's 2019 report lists about 846,500 tonnes of thorium in India's monazite deposits, based on 2010–2011 estimates. This total includes identified and undiscovered resources. The third and final core of the Shippingport Atomic Power Station 60 MWe reactor was a light water thorium breeder, which began operating in 1977. It used pellets made of thorium dioxide and uranium-233 oxide; initially, the U-233 content of the pellets was 5–6% in the seed region, 1.5–3% in the blanket region, and none in the reflector region. It operated at 236 MWt, generating 60 MWe, and ultimately produced over 2.1 billion kilowatt hours of electricity. After five years, the core was removed and found to contain nearly 1.4% more fissile material than when it was installed, demonstrating that breeding from thorium had occurred. A liquid fluoride thorium reactor is also planned as a thorium thermal breeder. Liquid-fluoride reactors may have attractive features, such as inherent safety, no need to manufacture fuel rods, and possibly simpler reprocessing of the liquid fuel. This concept was first investigated at the Oak Ridge National Laboratory Molten-Salt Reactor Experiment in the 1960s. From 2012 it became the subject of renewed interest worldwide.
Sources: en.wikipedia.org
=== Function === Mitochondrial fatty acid synthesis plays a crucial role in cellular energy metabolism by generating octanoyl‑ACP (C8), which serves as the direct precursor for lipoic acid biosynthesis. Lipoic acid is an essential cofactor covalently attached to specific lysine residues on target enzymes in a process called lipoylation. This post‑translational modification is essential for the activity of key mitochondrial enzyme complexes—namely, the pyruvate dehydrogenase complex (PDC), the α‑ketoglutarate dehydrogenase complex (OGDC), the 2-oxoadipate dehydrogenase complex (2‑OADHC), the branched‑chain α‑ketoacid dehydrogenase complex (BCKDC), and the glycine cleavage system (GCS). In parallel, mtFAS and its acyl‑ACP products provide a metabolic feedback mechanism, regulating mitochondrial acetyl‑CoA consumption and thereby integrating lipid synthesis with broader metabolic control. Beyond octanoyl‑ACP, mtFAS also produces longer‑chain acyl‑ACP species such as myristoyl‑ACP (C14) and palmitoyl‑ACP (C16), which interact with members of the leucine‑tyrosine‑arginine motif (LYRM) protein family. These LYRM proteins are vital for the correct assembly and stability of the electron‑transport chain (ETC) complexes and for iron–sulfur (Fe–S) cluster biogenesis within mitochondria. In addition to these enzymatic and structural roles, mtFAS has also been implicated as a mediator of intracellular signal transduction. This is supported by observations that the levels of bioactive lipids—such as lysophospholipids and sphingolipids—correlate with mtFAS activity.
There will probably never be another Test match like this. The tension generated by the closeness and importance of the game, combined with the efforts of the protestors inside, outside and above the ground, made for an exhilarating and yet terrifying afternoon. The role of the NZ police also became more controversial as a result of the tour. The NZRFU constitution contained much high-minded wording about promoting the image of rugby and New Zealand, and generally being a benefit to society. In 1985 the NZRFU proposed an All Black tour of South Africa that remobilised New Zealand protesters. Two lawyers successfully sued it, claiming such a tour would breach its constitution. The High Court stopped the tour.
Initially, Owens believed the Wests had been sincere in their apologies and obliged, believing she had simply mistaken their earlier intentions. Rose joined her in the back seat, with the explanation she wanted a "girls' chat" as Fred drove. Shortly thereafter, Rose began to fondle Owens, as Fred questioned whether she had had sex with her boyfriend that evening. When Owens began to protest, Fred stopped the car, referred to Owens as a "bitch" and punched her into unconsciousness before he and Rose bound and gagged her with a scarf and duct tape. In her subsequent statement to police, Owens stated that, at Cromwell Street, she was given a drugged cup of tea to drink before being again gagged and subjected to a prolonged sexual assault from the Wests. When Owens screamed, Rose smothered her with a pillow, further restrained her about the neck and performed cunnilingus on her. Realising the gravity of her situation, Owens ceased resisting their sexual assaults. The following morning, having noted Owens' screaming when one of his children had knocked on the door of the room in which she was restrained, Fred threatened that he and his wife would keep her locked in the cellar and allow his "black friends" to abuse her, and that when they had finished he would bury her body beneath "the paving stones of Gloucester." Fred then claimed he had killed hundreds of young girls, adding that Owens had primarily been brought to the house for "Rose's pleasure." He and Rose then calmly asked Owens whether she would consider returning to work as their nanny.
Sources: en.wikipedia.org
Geraniol 8-hydroxylase is a cytochrome P450 protein containing heme. It requires a partner cytochrome P450 reductase for functional expression. This uses nicotinamide adenine dinucleotide phosphate (NADPH).
== External links == Alberts, Bruce; Johnson, Alexander; Lewis, Julian, eds. (2002). "Fibroblasts and Their Transformations: The Connective-Tissue Cell Family". Molecular Biology of the Cell (4th ed.). New York: Garland Science. ISBN 978-0-8153-3218-3. Akita, Sadanori; Akino, Kozo; Imaizumi, Toshifumi; Hirano, Akiyoshi (2008). "Basic fibroblast growth factor accelerates and improves second-degree burn wound healing". Wound Repair and Regeneration. 16 (5): 635–41. doi:10.1111/j.1524-475X.2008.00414.x. PMID 19128258. S2CID 24954846. Phan, S. H. (2008). "Biology of Fibroblasts and Myofibroblasts". Proceedings of the American Thoracic Society. 5 (3): 334–7. doi:10.1513/pats.200708-146DR. PMC 2645244. PMID 18403329. Lapouge, Gaelle; Blanpain, Cédric (September 18, 2008). Silberstein, Leslie (ed.). "Medical applications of epidermal stem cells". Stembook. doi:10.3824/stembook.1.27.1. PMID 20614607.
International Journal of Pharmaceutics Volume 215 Issue 1-2 Pages 45–50 (2001) Chromatography: Separation and Indirect Detection of Amino-acids by Reversed Phase ion-pair Chromatography. Journal of Chromatographic Science Volume 31 Issue 11 Pages 480-485 (1993) Determination of pore/protein size via electrophoresis and slit sieve model. Electrophoresis Volume 25 Issue 17 Pages 2907-2911 (2004)
Morgan William Sulzer (1884), governor of New York J. Mayhew Wainwright (1884), U.S. congressman and assistant secretary of war Charles Henry Turner (1888), U.S. congressman from New York; doorkeeper of the United States House of Representatives 1891–1893 James W. Gerard (1890), U.S. ambassador to Germany 1913–1917 Victor M. Allen (1892), member of the New York State Senate John F. Carew (1893), U.S. congressman from New York Harvey R. Kingsley (1893), president pro tempore of the Vermont State Senate Edward Lazansky (1895), secretary of state of New York Carl L. Alsberg (1896), 2nd commissioner of Food and Drugs, head of the Food and Drug Administration 1912–1921 Lewis Einstein (1898), U.S. ambassador to Czechoslovakia and U.S. ambassador to Costa Rica John Purroy Mitchel (1899), mayor of New York City Montgomery Schuyler Jr. (1899), U.S. minister to El Salvador and U.S. minister to Ecuador Charles H. Tuttle (1899), U.S. attorney for the Southern District of New York and 1930 Republican nominee for governor of New York Henry W. Shoemaker (1901), folklorist, historian, diplomat; U.S. ambassador to Bulgaria 1930–1933 Martin C. Ansorge (1903), U.S. congressman from New York Stanley M. Isaacs (1903), Manhattan borough president 1938–1942 Allen J. Bloomfield (1094), member of the New York State Assembly and the New York State Senate Fred Biermann (1905), U.S. congressman from Iowa John Collier (1906), U.S. commissioner of Indian Affairs Meyer Robert Guggenheim* (1907), U.S. ambassador to Portugal 1953–1954, grandson of Meyer Guggenheim Joseph C.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.